We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3311:HKEXChina State Construction International Holdings Limited Analysis

Data as of 2026-03-15 - not real-time

HK$9.38

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock trades at HK$9.38, well below its 20‑day SMA of 9.46 and its 50‑day SMA of 9.27, indicating limited upward momentum. However, the price sits comfortably above the computed support of HK$9.07 and below the resistance of HK$9.87, offering a modest upside cushion. The MACD histogram is negative and the signal line is bearish, suggesting short‑term momentum weakness. RSI at 49 is neutral, so the stock is not oversold. The beta of –0.13 points to minimal correlation with the broader market, while 30‑day volatility of 24% signals price swings. Fundamentally, the trailing P/E of 4.6 versus an industry average of 29.1 marks the company as deeply undervalued. The price‑to‑book of 0.72 and price‑to‑sales of 0.43 reinforce the discount. A dividend yield of 7.25% with a payout ratio of 31.5% makes the dividend appear sustainable.
Analyst consensus (9 analysts) rates the stock as a strong buy with a median target of HK$13.5, implying ~38% upside. The company generates solid operating cash flow and maintains a ROE of 13%, supporting earnings durability. While leverage is high (debt‑to‑equity >100%), the strong cash position cushions solvency concerns. Given the attractive valuation, robust dividend, and supportive fundamentals, the stock presents a compelling buying opportunity across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bearish MACD but price above support
  • Strong dividend yield
  • Undervalued relative to peers

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Target price suggests 38% upside
  • Stable earnings and cash flow
  • Low market correlation

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑run infrastructure demand in China
  • Sustainable dividend income
  • Significant valuation discount

Key Metrics & Analysis

Financial Health

Revenue Growth0.10%
Profit Margin8.62%
P/E Ratio4.6
ROE13.11%
ROA3.44%
Debt/Equity108.10
P/B Ratio0.7
Op. Cash FlowHK$2.1B
Free Cash FlowHK$3.6B
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI49.3
SupportHK$9.07
ResistanceHK$9.87
MA 20HK$9.46
MA 50HK$9.27
MA 200HK$10.31
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Target PriceHK$13.02
Upside/Downside38.84%
GradeUndervalued
TypeValue
Dividend Yield7.25%

Risk Assessment

Beta-0.13
Volatility24.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.